Enzalutamide Clinical Trials

Browse 9 Enzalutamide Medical Studies Across 116 Cities

3 Phase 3 Trial · 176 Enzalutamide Clinics

Reviewed by Michael Gill, B. Sc.
9 Enzalutamide Clinical Trials Near Me
Top Cities for Enzalutamide Clinical Trials
Image of Nashville in Tennessee.
Nashville
10Active Trials
Tennessee Oncology, PLLCTop Active Site
Image of Boston in Massachusetts.
Boston
9Active Trials
Dana-Farber Cancer InstituteTop Active Site
Enzalutamide Clinical Trials by Phase of Trial
Phase 1 & 2 Enzalutamide Clinical Trials
3Active Enzalutamide Clinical Trials
3Number of Unique Treatments
52Number of Active Locations
Most Recent Enzalutamide Clinical Trials
Clinical Trial
Began Recruiting Date
Phase

What Are Enzalutamide Clinical Trials?

Enzalutamide clinical trials are research studies that help test the effectiveness of the medication. The medication is used as a treatment for prostate cancer.

Current treatments for prostate cancer include surgery, radiation therapy, and hormone therapy. Enzalutamide is a new type of medication that blocks testosterone's activity. This may help to slow the growth of cancer cells.

Enzalutamide clinical trials are being conducted to see if this medication effectively treats prostate cancer. These trials are also being conducted to compare Enzalutamide's effectiveness with other prostate cancer treatments.

Why Is Enzalutamide Being Studied in Clinical Trials?

Enzalutamide has recently been FDA-approved for prostate cancer treatment that has spread to other parts of the body and is resistant to hormone therapy. Enzalutamide clinical trials are being conducted to test the medication's effectiveness in treating this type of prostate cancer.

Enzalutamide is hypothesized to be more effective than current prostate cancer treatments. It may also have fewer side effects than other prostate cancer treatments.

Common treatments for prostate cancer are surgery, radiation therapy, and hormone therapy. Surgery may not be the best treatment because it can cause urinary incontinence and erectile dysfunction.

Radiation therapy may not be the best treatment because it can cause fatigue and skin problems. Hormone therapy may not be the best treatment because it can cause hot flashes, weight gain, and loss of bone density. Enzalutamide clinical trials are being conducted to see if this medication is an effective treatment with fewer side effects.

How Does Enzalutamide Work?

Enzalutamide works by blocking testosterone's activity. This may help to slow the growth of cancer cells.

Testosterone is a hormone that helps to stimulate the growth of prostate cancer cells. Enzalutamide works by binding to the androgen receptor, and the protein testosterone binds to it. The chemical blocks testosterone from binding to the androgen receptor and may help slow cancer cell growth.

Enzalutamide may also help kill cancer cells and prevent them from growing and spreading. However, it may work better when combined with other prostate cancer treatments.

What Are Some of The Breakthrough Clinical Trials Involving Enzalutamide?

Some breakthrough clinical trials with Enzalutamide include:

2013: A clinical study tested the first round of Phase I tests on males with prostate cancer using Enzalutamide. The results proved that Enzalutamide was well tolerated by the patients and had a good safety profile.

2017: This study found that Enzalutamide, in combination with Endocrine Therapies, was a well-tolerated treatment option for women with advanced breast cancer. This was a breakthrough because it was unclear if Enzalutamide would effectively treat other types of cancer.

2023: Enzalutamide was tested to see if it was more effective than Bicalutamide in patients with nonmetastatic castration-resistant prostate cancer. The findings were that Enzalutamide lowered the risk progression of death better than Bicalutamide.

Who Are The Key Opinion Leaders On Enzalutamide Clinical Trial Research?

Dr. Maha Hussain: She is the Director of the USC Norris Comprehensive Cancer Center and a Professor of Medicine at the Keck School of Medicine of USC.

Dr. Scott Eggener: He is a Professor of Surgery and Urology at the University of Chicago. He has also been involved in Enzalutamide clinical trials and is a leading expert in the field.

Dr. Christopher Sweeney is a Medicine Professor at the Dana-Farber Cancer Institute and Harvard Medical School. He is also the Director of Genitourinary Oncology at the Dana-Farber Cancer Institute.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: August 16th, 2023

References1 Rodríguez Y, Unno K, Truica MI, Chalmers ZR, Yoo YA, Vatapalli R, Sagar V, Yu J, Lysy B, Hussain M, Han H, Abdulkadir SA. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2022 Jun 6;82(11):2110-2123. doi: 10.1158/0008-5472.CAN-21-3565. https://pubmed.ncbi.nlm.nih.gov/354050092 Rodriguez Y, Unno K, Truica MI, Chalmers ZR, Yoo YA, Vatapalli R, Sagar V, Yu J, Lysy B, Hussain M, Han H, Abdulkadir SA. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2022 Jun 6;82(11):2110-2123. doi: 10.1158/0008-5472.CAN-21-3565. https://pubmed.ncbi.nlm.nih.gov/354050093 Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. https://pubmed.ncbi.nlm.nih.gov/311579644 Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. J Clin Oncol. 2022 Mar 10;40(8):837-846. doi: 10.1200/JCO.21.00941. Epub 2021 Dec 20. https://pubmed.ncbi.nlm.nih.gov/349287085 Davis ID. Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer. Eur Urol. 2018 Jun;73(6):856-858. doi: 10.1016/j.eururo.2018.02.020. Epub 2018 Mar 7. No abstract available. https://pubmed.ncbi.nlm.nih.gov/295255416 Davis ID. Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer. Eur Urol. 2018 Jun;73(6):856-858. doi: 10.1016/j.eururo.2018.02.020. Epub 2018 Mar 7. https://pubmed.ncbi.nlm.nih.gov/29525541